CNBXOTCPharmaceutical PreparationsFiscal year ends August 31
CNBX Pharmaceuticals Inc.
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jun 24, 2026
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $197.79K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0003 (−60.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
CNBX Pharmaceuticals Inc. reported revenue of $0 for the twelve months to May 31, 2026.
Revenue
$0
TTM Q3 2026
Operating income
-$429.46K
TTM Q3 2026
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at May 31, 2026
Valuation
- Market cap
- $197.79K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$462.09K
- EPS, diluted
- $0.00
- Book value per share
- -$0.00
- Diluted shares
- 1.32B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$0
Gross profit
–
Operating income
-$429.46K
Net income
-$462.09K
EPS, diluted
–
Reported periodTrailing twelve months